drugset / Trial / NCT02651090

Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI

NCT02651090

NaSingle-groupOpen-labelDiagnostic

Summary

Patients with renal failure or other reason for contraindication for contrast enhanced computed tomography (CECT) or contrast enhanced magnetic resonance imaging (CEMRI) with suspected liver pathology will be evaluated with Sonazoid enhanced Ultrasound

Timeline

Start
2017-10
Primary completion
2018-03
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Perflubutane Diagnostic / imaging agent Intravenous

Indications

No indication recorded.